Last reviewed · How we verify
Chronic ulcerative rectosigmoiditis
Approved treatments
- Rowasa · Meda Pharms
Rowasa works by blocking the production of prostaglandins, which are chemicals that cause inflammation in the rectum and colon. - MESA · Meda Pharms
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Chronic ulcerative rectosigmoiditis patent landscape — cliff calendar, originator estates, attackable patents
- Chronic ulcerative rectosigmoiditis treatment landscape brief
- Chronic ulcerative rectosigmoiditis treatment updates RSS
Frequently asked questions about Chronic ulcerative rectosigmoiditis
What drugs treat Chronic ulcerative rectosigmoiditis?
Tracked treatments include Rowasa, MESA.
What is the treatment for Chronic ulcerative rectosigmoiditis?
Standard treatment for Chronic ulcerative rectosigmoiditis includes Rowasa, MESA. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Chronic ulcerative rectosigmoiditis patent cliff · Chronic ulcerative rectosigmoiditis CI report
- Treatment: Rowasa · Meda Pharms
- Treatment: MESA · Meda Pharms
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing